1 / 1

Validating five questions of antiretroviral non-adherence in a decentralized

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda Chaiyachati 1-3 , Lisa R Hirschhorn 4,5 , , Frank Tanser2, Marie-Louise Newell 2,6 , Till Bärnighausen 2,3

rollo
Download Presentation

Validating five questions of antiretroviral non-adherence in a decentralized

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda Chaiyachati1-3, Lisa R Hirschhorn4,5, , Frank Tanser2, Marie-Louise Newell2,6, Till Bärnighausen2,3 1Yale Primary Care Internal Medicine Residency Program, New Haven and Waterbury, Connecticut; 2Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa; 3Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts; 4Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; 5John Snow Institute, Research and Training, Boston, Massachusetts; 6Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, London, UK Background Methods Results Summary • Five assessments of ART adherence administered were: • 7-day recall of missed doses • 7-day recall of late doses (missed by >2 hours) • A six-level Likert scale of adherence (“excellent” to “very poor”) • 30-day visual analogue scale (VAS, proportion of pills missed) • Question on the last dose missed within seven discrete time periods. • Questions were validated in their performance to detect treatment failure at 6 months: • Immunologic failure: CD4 <100 cells/mm3 after 6 months (+/- 45 days) of ART • OR • Virologic failure: VL >400 copies/ml after previously undetectable VL or VL >10,000 copies/ml after 6 months (+/- 45 days) of ART • Sensitivities and specificities in predicting treatment failure at 6 months were calculated. • Further analyses of performance: • At 3 months and beyond 6 months • Combining immunologic or virologic failure as a possible outcome • Combinations of highly sensitive (screen) then highly specific (confirm) questions • Stratification by sex, age (> or < 35 years), and education level (> or < secondary education) • Medication adherence is important for treatment success, especially for chronic conditions like HIV • Instruments to measure ART adherence identify patients needing treatment support, preventing treatment failure and the development of resistance • Simple questions are often used to measure ART adherence in sub-Saharan Africa (SSA) • Self-reported adherence tools have rarely been independently validated • The Likert item screened immunologic or virologic failures best, but with poor specificity • Altering the time of follow-up, combining outcomes or questions, and stratification did not significantly improve the performance of adherence questions Limitations • Cross-sectional approach • Alternative reasons for treatment failure: • Primary and secondary HIV resistance • Malabsorption or vomiting • Drug interactions, especially tuberculosis or traditional medication • Lag time between adherence and treatment response Objective • Validate the performance of five commonly used ART adherence questions against a gold standard of treatment failure Enrollment • Inclusion: ART experienced >2 weeks, viral load (VL) or CD4 count within 6 weeks of enrolment, and age > 18 years • Excluded: Pregnant individuals or anticipated ART discontinuation within 6 months Conclusions • No single question or combination of questions had sensitivity and specificity appropriate for screening purposes and resource allocation, respectively • Valid tools for measuring adherence are urgently needed in SSA to identify patients for treatment support and those at risk of treatment failure • These lessons can extend to the management of non-communicable diseases Setting • A public sector, decentralized ART program in rural KwaZulu-Natal, South Africa between 2007-08 Citation Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Bärnighausen T. Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDS. 2011 Mar; 25(3): 163-70.

More Related